# CS-E5875 High-Throughput Bioinformatics Immune cell receptor sequencing 

Harri Lähdesmäki<br>(most slides by Emmi Jokinen)<br>Department of Computer Science<br>Aalto University

November 27, 2020

## Outline

- Immune system, T cells and T cell receptors
- Motivation and objectives
- TCR sequencing data
- Kernel methods
- Gaussian processes
- Results


## Outline

- Immune system, $T$ cells and $T$ cell receptors
- Motivation and objectives
- TCR sequencing data
- Kernel methods
- Gaussian processes
- Results


## Human immune system

- Humans are exposed to millions of potential pathogens daily, through contact, ingestion, and inhalation.

INNATE
IMMUNE RESPONSES

## Innate Immune responses

- General defence reactions
- Three lines of defences:
- Physical and chemical barriers
- Cell-intrinsic responses
- An individual cell recognizes that it has been infected and takes measures to kill or cripple the invader
- A specialized set of proteins and phagocytic cells that recognize conserved features of pathogens and become quickly activated to help destroy invaders


## Adaptive immune responses

- Highly specific responses
- Slow to develop on first exposure to a new pathogen (can take a week or so)
- Provide long-term protection
- Activated by innate immune system
- Carried out by lymphocytes
- Antibody responses (B cells)
- T-cell-mediated responses


## T cells



- T cells are white blood cells (lymphocytes) that are distinguished from other lymphocytes by the presence of a T-cell receptor (TCR) on the cell surface
- T cells play a central role in the immune response


## T cells and T cell receptors (TCRs)



Tcell
activated dendritic cell

- T cells are activated by foreign antigens (peptides)
- Peptides are displayed by major histocompatibility complex (MHC) proteins located on the surface of antigen-presenting cells (usually dendritic cells)
- Peptide-MHC complex is recognised by T cell receptor (TCR)
- Upon T cell activation via TCR, T cells proliferate and differentiate into effector cells


## T cell receptors (TCRs)



- The T-cell receptor (TCR) gene is expressed in T cells and found on the surface of $T$ cells
- The TCR is a heterodimer composed of two different protein chains, alpha and beta
- Antigen (peptide) specificity is determined by hyper variable loops, so-called complementary determining regions (CDR) 1, 2 and 3


## TCR diversity

- Each individual T cell can (in principle, but not in practice) have a unique TCR gene in DNA: different TCRs recognise different peptides
- V(D)J recombination: TCRs are manufactured from variable (V), diversity (D), joining (J) and constant (C) gene fragments through a process of somatic gene rearrangement
(a)

(b)


Figure: [5]

## TCR diversity

- TCR $\alpha$ chain locus: 45 V -gene and 50 J -gene segments
- TCR $\beta$ chain locus: ~50 V-gene, 2 D-gene and 12 J-gene segments
- Junctional diversification: During the joining of these gene segments nucleotides can be lost from the ends of the segments, and one or more can also be inserted


Figure: Cellular and Molecular Immunology. Abul K. Abbas, Andrew H. H. Lichtman, Shiv

## Antigen-binding site



Figure: [1]

- CDR3 primarily interacts with the peptide and is most variable
- CDR1 and CDR2 (and CDR2.5) mainly bind to the walls of the peptide-binding groove, but have sometimes been observed to be in contact with the peptide



## TCR repertoire

- Each T cell has potentially an unique TCR
- TCRs of an individual are called a TCR repertoire
- After a T cell has recognized an epitope, it starts to proliferate
- The resulting set of T cells with identical TCRs is called a clone
- T cells from large clones are more likely to be sampled
- TCR repertoire contains an immunological memory of all immunological stimuli an individual has had during lifetime
- Viruses, microbes, other environmental exposures
- Vaccines


## Complexity of TCR repertoires

- ~1018 possible TCRs
- $\sim 10^{12} \mathrm{~T}$ cells in a human
- $\sim 10^{8}$ distinct TCRs in a human (young adult)
- If a sample contains e.g. around 50000 T cells
- It's about $0.000005 \%$ of all T cells
- On average, each T cell recognises at least 1 million individual peptides
- A peptide can be recognised by several TCRs.


## Outline

- Immune system, T cells and T cell receptors
- Motivation and objectives
- TCR sequencing data
- Kernel methods
- Gaussian processes
- Results


## How to utilize TCRs?

Improved diagnostics

- Better understanding of an individual's immune status in different diseases

Personalized medicine

- Which patients would respond to different medications?

Repertoire level studies: utilize TCR repertoires of different subjects

- E.g. find TCRs associated with some condition Sequence level studies
- E.g. determine epitope specificity of individual TCRs


## Another Goal

receptor for co-stimulatory protein

- Determine which peptides bind a given MHC
foreign peptide (antigen)



## Why machine learning?

- "Perfect" solution:
- Test experimentally which peptides all possible TCRs (~1018) recognize
- Impossible
- Machine learning solution:
- Assume that similar TCRs behave similarly
- Based on known specificities of some TCRs, predict specificities for new TCRs (supervised learning)


## Supervised learning

- A learning process which looks at annotated data to
receptor for co-stimulatory
protein then automatically annotate similar un-annotated data


## Classification task

- Binary classification:
- Predict whether a TCR recognizes and binds to a certain peptide or not
cell-cell
adhesion
proteins
foreign peptide (antigen)


MHC protein

## Outline

- Immune system, T cells and T cell receptors
- Motivation and objectives
- TCR sequencing data
- Kernel methods
- Gaussian processes
- Results


## TCR sequencing

- TCRs can be quantified by sequencing
- Targeted sequencing for TCR locus in DNA using C-gene selective primer (TCR-seq)
- RNA-seq
- Additionally, one can first select T cells that recognize a specific peptide, and sequence the TCR gene from only those cells
- Epitope-specific, tetramer-sorted TCRseq


Figure: [6]

## Quantification of TCRs from TCR-seq

- Align TCR-seq sequencing reads against V, D and J genes
- Similar to RNA-seq read alignment but with lots of mismatches and indels
- Several tools: e.g. MiXCR



## Quantification of TCRs from TCR-seq

- Align TCR-seq sequencing reads against V, D and J genes
- Similar to RNA-seq read alignment but with lots of mismatches and indels
- Several tools: e.g. MiXCR


Figure: https://mixcr.readthedocs.io/en/master/

## Epitope-specific TCRs

- Epitope-specific TCRs are stored e.g. in VDJdb https://vdjdb.cdr3.net
- TCRs recognizing epitopes from e.g.
- Influenza A
- Cytomegalovirus
- HIV
- Epstain Barr Virus
- Sars-Cov-2

Distribution VDJdb confidence scores


VDJdb score $\square$ 0 , ${ }^{2} \square^{3}$

0 - critical information missing, 1 -medium confidence,
2 - high confidence, 3 -very high confidence.

## Control sequences

- Negative controls may also be needed (e.g. for supervised analysis)
- Generally TCRs that recognize an epitope are sequenced, not TCRs that do not recognize that epitope
- We can take TCRs that appear only once (singletons) in a subject's TCR reportoire
- We can assume that these TCRs are unlikely to recognize a certain epitope


## TCR amino acid sequences

- Usually a TCR is presented by its CDR3 amino acid sequence and V - and J -genes
- CDR1, CDR2 and CDR2.5 are completely determined by V -gene and allele

- We can construct a table of CDR1, CDR2 and CDR2.5 sequences corresponding to all possible V-genes and alleles
- Examples of TCR $\beta$ sequences:

| CDR3 | CDR1 | CDR2 | CDR2.5 |
| :--- | :--- | :--- | :--- |
| CASSIQALLTF | SGHDY | FNNNVP | PNASF |
| CASSVVGGNEQFF | SGDLS | YYNGEE | FPDLH |
| CASSVAQLAGGTDTQYF | SGDLS | YYNGEE | FPDLH |
| CSARDPSGLAGGLAETQYF | DFQATT | SNEGSKA | ASLTL |

## How to utilize sequences?

No alignment
CASSIQALLTF
CASSVVGGNEQFF
CASSVAQLAGGTDTQYF
CSARDPSGLAGGLAETQYF

With alignment
CASSIQ--------ALLTF
CASSVVG------GNEQFF
CASSVAQLA--GGTDTQYF
CSARDPSGLAGGLAETQYF

- Alignment free methods
+ Sequences can have arbitrary lenghts
- Cannot consider position specific information
- Methods that use aligned sequences
+ Can utilize position specific information
+ Can utilize amino acid features (more easily)
- Good alignment can be difficult to get
- New sequences need to be added to the alignment
- New sequences cannot be longer than those in the original alignment


## Alignment-free comparisons

- Edit distance: Levenshtein distance
- Minimum number of single amino acid changes (insertions, deletions, substitutions) between two sequences:
-CASSLYF $\rightarrow$ CAASSLYF $\rightarrow$ CAASLYW: distance is 3
- k-mer or motif freqưencies
- Define a set of k-mers, all possible or some smaller set
- Can be used to define "similar" TCRs

|  | CAS ASS |  | SSL SLY | $\cdots$ |  |
| :--- | :--- | :--- | :--- | :--- | :--- |
| CASSLYFF | 1 | 1 | 1 | 1 | $\cdots$ |
| CASSIQALLTF | 1 | 1 | 0 | 0 | $\cdots$ |
| CASSVVGGNEQFF | 1 | 1 | 0 | 0 | $\cdots$ |
| CAVGDRGYEQYF | 0 | 0 | 0 | 0 | $\cdots$ |
| $\vdots$ | $\vdots$ | $\vdots$ | $\vdots$ | $\vdots$ | $\ddots$ |

- Do not consider similarity between amino acids


## Aligning TCR sequences

- There is a limited number of CDR1, CDR2 and CDR2.5 sequences, and we know what they are
- They can all be aligned according to IMGT definitions
- We assume that CDR3 sequences form simple loops
- We add gap at the top of the loop for shorter sequences (according to IMGT numbering)
- Easy to add new sequences to the alignment
- Examples of aligned TCR $\beta$ sequences

| CDR3 | CDR1 | CDR2 | CDR2.5 |
| :---: | :---: | :---: | :--- |
| CASSIQ--------ALLTF | SGH--------DY | FNN----NVP | P-NASF |
| CASSVVG------GNEQFF | SGD-------LS | YYN----GEE | F-PDLH |
| CASSVAQLA--GGTDTQYF | SGD--------LS | YYN----GEE | F-PDLH |
| CSARDPSGLAGGLAETQYF | DFQ-------ATT | SNEG---SKA | A-SLTL |

## One-hot encoding

- Most simple numeric presentation
- Sequences as vectors with constant length
- Does not consider similarity between amino acids

| A R | N | D | E | Q | G | H | L | L | K | M | F | P | S | T | W | Y | V | - |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |


| C | A | S | S | - | - | - | $L$ | Y | F | F |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |

## Amino acid properties

- There are 20 naturally occurring amino acids
- R-groups (or side chains) determine their different properties H

| Amino acid | Abbreviation |  | Chemical | Volume | Hydropathy |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Alanine | Ala | A | alipahatic | 87 | hydrophobic |
| Arginine | Arg | R | basic | 173 | hydrophilic |
| Aspargine | Asn | N | amide | 114 | hydrophilic |
| Aspartic acid | Asp | D | acid | 111 | hydrophilic |
| Cysteine | Cys | C | sulfur | 109 | hydrophobic |
| Glutamic acid | Glu | E | acid | 138 | hydrophilic |
| Glutamine | Gln | Q | amide | 144 | hydrophilic |
| Glysine | Gly | G | aliphatic | 60 | neutral |
| Histidine | His | H | basic | 153 | neutral |
| Isoleucine | Ile | I | alipahatic | 167 | hydrophobic |
| Leucine | Leu | L | alipahatic | 167 | hydrophobic |
| Lycine | Lys | K | basic | 169 | hydrophilic |
| Methionine | Met | M | sulfur | 163 | hydrophobic |
| Phenyalanine | Phe | F | aromatic | 190 | hydrophobic |
| Proline | Pro | P | Cyclic | 113 | neutral |
| Serine | Ser | S | hydroxyl | 89 | neutral |
| Threonine | Thr | T | hydroxyl | 116 | neutral |
| Tryptohophan | Trp | W | aromatic | 228 | hydrophobic |
| Tyrosine | Tyr | Y | aromatic | 194 | neutral |
| Valine | Val | V | alipahatic | 140 | hydrophobic |
|  |  |  |  |  |  |

# Feature presentation 

- Use the different amino acid properties as features
- Concatenate them to make feature vectors for each amino acid, e.g.
$\left[\begin{array}{c}\text { volume } \\ \text { charge } \\ \text { hydrophobicity } \\ \text { polarity }\end{array}\right]$



# Substitution matrices 

BLOSUM62

- Describe how easily an amino acid can be substitued with another
- Can be based e.g. on:
- Sequence comparison
- Sequence comparison by protein blocks
- Chemical similarity
- Structural or physical similarity

With added gap (-) and scaled into range [0,1]

BLOSUM62

## Amino acid features with BLOSUM62

## PCA of BLOSUM62

$\rightarrow$ feature vectors (size: $d \times 1$ ) for each amino acid

## CDR3 presentation with BLOSUM62

 ecoSequence presentation (size: $/ \times d$ or $(I \cdot d) \times 1$ )
C A S S Y K K - - - - T E G G D P

## Outline

- Immune system, T cells and T cell receptors
- Motivation and objectives
- TCR sequencing data
- Kernel methods
- Gaussian processes
- Results


## Classification



- Linear classification
- Fairly simple

- Non-linear classification
- More difficult
- Can be implemented with kernels


## Kernels (1/3)

- Kernel functions allow us to encode the similarity of TCRs
- Kernels can map data $\mathrm{x} \in \mathscr{X}$ to a higher dimensional space $\mathscr{H}$, where it is linearly separable



## Kernels (2/3)

- Definition:

For a non-empty set $\mathcal{X}$, a function $k: \mathcal{X} \times \mathcal{X} \rightarrow \mathbb{R}$ is a kernel if there exists a Hilbert space $\mathcal{H}$ and a function $\phi: \mathcal{X} \rightarrow \mathcal{H}$ such that $\forall x, x^{\prime} \in \mathcal{X}, k\left(x, x^{\prime}\right):=\left\langle\phi(x), \phi\left(x^{\prime}\right)\right\rangle_{\mathcal{H}}$

- A commonly used kernel is Gaussian kernel (or radial basis function (RBF) or squared exponential (SE)):

$$
k\left(\mathbf{x}, \mathbf{x}^{\prime} \mid \theta\right)=\sigma^{2} \exp \left(-\frac{\left(\mathbf{x}-\mathbf{x}^{\prime}\right)^{T}\left(\mathbf{x}-\mathbf{x}^{\prime}\right)}{2 \ell^{2}}\right)
$$

where $\ell$ is the length-scale parameter, $\sigma^{2}$ is the magnitude parameter and $\theta=\left(\ell, \sigma^{2}\right)$.

## Kernels (3/3)

- Examples of kernel functions:


Matern32


Linear


Matern52


Cosine


SquaredExponential


Periodic


Figure: https://gpflow.readthedocs.io/en/develop/notebooks/kernels.html

## Outline

- Immune system, T cells and T cell receptors
- Motivation and objectives
- TCR sequencing data
- Kernel methods
- Gaussian processes
- Results


## GP classification

- A probabilistic classifier that uses kernels
- Can learn non-linear decision boundaries
- Learns suitable complexity of the boundary from data
- Models the confidence of the predictions




## TCRGP pipeline



# Epitope-specific TCR data 

| Dash data |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Species | Epitope species | Epitope gene | Epitope | MHC <br> chain 1 | MHC chain 2 | Subjects | Samples | Unique <br> $\operatorname{TCR} \alpha \beta \mathrm{s}$ |
| Human | EBV | BMLF $1_{280-288}$ | GLCTLVAML | HLA-A*02:01 | - | 6 | 76 | 69 |
|  | CMV | pp65495-503 | NLVPMVATV | HLA-A*02:01 | - | 10 | 61 | 60 |
|  | IAV | $\mathrm{M} 1_{58-66}$ | GILGFVFTL | HLA-A*02:01 | - | 15 | 275 | 237 |
| Mouse | IAV | PB1-F2 ${ }_{62-70}$ | LSLRNPILV | $\mathrm{D}^{\text {b }}$ | - | 9 | 117 | 117 |
|  | IAV | $\mathrm{NP}_{366-374}$ | ASNENMETM | $\mathrm{D}^{\text {b }}$ | - | 24 | 305 | 263 |
|  | IAV | $\mathrm{PA}_{224-233}$ | SSLENFRAYV | $\mathrm{D}^{\text {b }}$ | - | 15 | 324 | 293 |
|  | IAV | PB1703-711 | SSYRRPVGI | $\mathrm{K}^{\text {b }}$ | - | 34 | 642 | 584 |
|  | mCMV | m139 ${ }_{419-426}$ | TVYGFCLL | $\mathrm{K}^{\text {b }}$ | - | 8 | 87 | 87 |
|  | mCMV | M38316-323 | SSPPMFRV | $\mathrm{K}^{\text {b }}$ | - | 14 | 158 | 143 |
|  | mCMV | M45985-993 | HGIRNASFI | $\mathrm{D}^{\text {b }}$ | - | 13 | 291 | 271 |
| VDJdb data |  |  |  |  |  |  |  |  |
| Human | CMV | pp65 ${ }_{123-131}$ | IPSINVHHY | HLA-B*35 | B2M | 17 | 65 | 58 |
|  | CMV | pp65 ${ }_{\text {417-426 }}$ | TPRVTGGGAM | HLA-B*07 | B2M | 29 | 184 | 122 |
|  | CMV | pp65 ${ }_{\text {495-503 }}$ | NLVPMVATV | HLA-A*02 | B2M | 103 | 413 | 242 |
|  | EBV | BMLF $1_{280-288}$ | GLCTLVAML | HLA-A*02 | B2M | 54 | 299 | 152 |
|  | EBV | BZLF $1_{190-197}$ | RAKFKQLL | HLA-B*08 | B2M | 17 | 225 | 149 |
|  | EBV | BRLF $1_{109-117}$ | YVLDHLIVV | HLA-A*02 | B2M | 6 | 66 | 51 |
|  | IAV | M1 ${ }_{\text {58-66 }}$ | GILGFVFTL | HLA-A*02 | B2M | 50 | 239 | 138 |
|  | IAV | $\mathrm{HA}_{306-318}$ | PKYVKQNTLKLAT | HLA-DRA*01 | HLA-DRB1*01,04 | 11 | 56 | 50 |
|  | HCV | NS31073-1081 | CINGVCWTV | HLA-A*02 | B2M | 7 | 76 | 39 |
|  | HCV | NS31406-1415 | KLVALGINAV | HLA-A*02 | B2M | 4 | 65 | 65 |
|  | HCV | NS31436-1445 | ATDALMTGY | HLA-A*01 | B2M | 7 | 152 | 139 |
|  | HSV-2 | VP22 ${ }_{49-57}$ | RPRGEVRFL | HLA-B*07 | B2M | 5 | 68 | 29 |
|  | YFV | NS4B ${ }_{214-222}$ | LLWNGPMAV | HLA-A*02 | B2M | 5 | 223 | 198 |
|  | DENV1 | NS3133-142 | GTSGSPIVNR | HLA-A*11 | B2M | 11 | 65 | 59 |
|  | DENV3-4 | NS3133-142 | GTSGSPIINR | HLA-A*11 | B2M | 8 | 51 | 46 |
|  | HIV-1 | p2430-40 | KAFSPEVIPMF | HLA-B*57 | B2M | 44 | 134 | 104 |
|  | HIV-1 | p2448-56 | TPQDLNTML | HLA-B* 42,81 | B2M | 21 | 52 | 40 |
|  | HIV-1 | p24 128-135 $^{\text {d }}$ | EIYKRWII | HLA-B*08 | B2M | 12 | 81 | 60 |
|  | HIV-1 | p24 ${ }_{131-140}$ | KRWIILGLNK | HLA-B*27 | B2M | 27 | 212 | 141 |
|  | HIV-1 | p24 161-180 | FRDYVDRFYKTLRAEQASQE | HLA-DRA*01 | HLA-DRB1* $01,07,11,15$, HLA-DRB5*01 | 17 | 141 | 95 |
|  | HIV-1 | $\mathrm{p} 24_{223-231}$ | GPGHKARVL | HLA-B*07 | B2M | 1 | 62 | 53 |
|  | HIV-1 | Nef ${ }_{90-97}$ | FLKEKGGL | HLA-B*08 | B2M | 21 | 104 | 78 |

## AUCs for 10 epitopes: Comparing TCRGP

 and TCRdist using leave-one-subject-out crossvalidation

## AUCs for 22 epitopes for VDJdb data: Comparing several methods



# How many epitope-selected TCRs are needed to build a reliable/robust prediction model? 



## Combining TCR-peptide recognition prediction with scRNA-seq analysis

- Can we gain more insight into diseases using combined TCR-seq+scRNA-seq?
- An example of HBV virus in hepatocellular carcinoma (HCC)


## Cheng data

HBV-specific TCR $\beta$ data

## Zheng data

T cells from HBV+ HCC

Analyze HBV-
specific T cells in HCC

## Analysis of TCR-seq+scRNAseq from HBV+ hepatocellular carsinoma patients

- Can identify which phenotypes HBVrecognizing T cells are enriched to
- Most exhausted and least functional



## Other references

[1] Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., and Walter, P. (2007). Molecular biology of the cell. Garland Science, 5 edition.
[2] Robins, H. S. et al. (2009). Comprehensive assessment of T-cell receptor $\beta$-chain diversity in $\alpha \beta$ T cells. Blood, 114(19), 4099-4107.
[3] Lefranc, M. (1999). The IMGT unique numbering for immunoglobulins, T-cell receptors, and Ig-like domains. Immunologist, 7(4), 132-136.
[4] Rasmussen, C. E. and Williams, C. K. I. (2006). Gaussian processes for machine learning. The MIT Press.
[5] Daniel Joseph Laydon, Charles R M Bangham, Becca Asquith (year). Estimating T-cell repertoire diversity: Limitations of classical estimators and a new approach.
[6] Scott Brown, Lisa A. Raeburn, Robert A. Holt (2015) Profiling tissue-resident T cell repertoires by RNA sequencing

